Fabtech Technologies Ltd
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company.[1]
- Market Cap ₹ 631 Cr.
- Current Price ₹ 142
- High / Low ₹ 258 / 115
- Stock P/E 21.2
- Book Value ₹ 98.8
- Dividend Yield 0.44 %
- ROCE 13.9 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Earnings include an other income of Rs.34.0 Cr.
- Company has high debtors of 215 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology
Part of Nifty IPO BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 133 | 121 | 257 | 194 | 226 | 327 | 411 | 388 | |
| Sales growth | -9% | +112% | -25% | +17% | +44% | +26% | -9% | |
| 119 | 110 | 225 | 169 | 191 | 288 | 374 | 363 | |
| Operating Profit | 14 | 11 | 32 | 25 | 35 | 39 | 37 | 25 |
| OPM % | 11% | 9% | 12% | 13% | 15% | 12% | 9% | 6% |
| 5 | 2 | 4 | 10 | 6 | 27 | 23 | 34 | |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 | 6 | 4 |
| Depreciation | 0 | 0 | 2 | 2 | 2 | 3 | 5 | 5 |
| Profit before tax | 16 | 11 | 31 | 28 | 36 | 60 | 48 | 50 |
| Tax % | 27% | 29% | 25% | 22% | 24% | 23% | 21% | |
| 12 | 8 | 23 | 22 | 27 | 46 | 38 | 36 | |
| EPS in Rs | 1,239.00 | 804.00 | 7.67 | 7.10 | 8.40 | 14.34 | 8.63 | 8.01 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 28% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 18% |
| TTM: | -47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 15% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 3 | 3 | 3 | 32 | 44 | 44 |
| Reserves | 38 | 46 | 65 | 86 | 129 | 141 | 375 | 395 |
| 1 | 9 | 21 | 35 | 13 | 84 | 70 | 57 | |
| 84 | 70 | 83 | 89 | 125 | 170 | 209 | 189 | |
| Total Liabilities | 123 | 126 | 172 | 214 | 269 | 427 | 699 | 686 |
| 2 | 2 | 5 | 4 | 22 | 94 | 78 | 75 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 12 | 7 | 17 | 20 | 21 | 15 | 29 | 29 |
| 109 | 116 | 150 | 190 | 226 | 318 | 591 | 582 | |
| Total Assets | 123 | 126 | 172 | 214 | 269 | 427 | 699 | 686 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 64 | -9 | -3 | -14 | 60 | -36 | 0 | |
| -28 | 4 | -9 | 2 | -30 | -20 | -112 | |
| -23 | 6 | 8 | 12 | -12 | 36 | 190 | |
| Net Cash Flow | 13 | 1 | -4 | -0 | 18 | -20 | 78 |
| Free Cash Flow | 64 | -9 | -4 | -14 | 59 | -61 | -4 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 417% | -65% | 4% | -15% | 196% | -68% | 34% |
Ratios
Consolidated / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 120 | 187 | 156 | 168 | 215 |
| Inventory Days | 22 | 39 | 17 | 69 | 88 | 119 | 32 |
| Days Payable | 82 | 150 | 136 | 215 | 195 | 198 | 215 |
| Cash Conversion Cycle | 51 | 25 | 1 | 41 | 49 | 89 | 32 |
| Working Capital Days | -19 | 15 | 30 | 65 | 63 | 53 | 79 |
| ROCE % | 26% | 48% | 31% | 28% | 22% | 14% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| New Orders Received INR Crore |
|
||||
| Order Book INR Crore |
|||||
| ECO Zone Share of New Orders % |
|||||
| GCC Share of New Orders % |
|||||
| MENA Share of New Orders % |
|||||
| Proposal to Order Conversion % |
|||||
| Turnkey Share of New Orders % |
|||||
| Number of New Orders Count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- Crisil monitoring report for Q2 FY2027 shows IPO proceeds utilization, with no deviations and 12,574.53 lakh unutilized.
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
- Mr. Kalpesh Chauhan resigns as CFO and KMP effective November 12, 2026.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Fabtech Technologies Limited has informed about Transcript
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Recorded earnings conference call for Q2 and half-year FY2026 results available online.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
Concalls
-
Nov 2026Transcript PPT REC
-
Aug 2026Transcript PPT REC
-
Jun 2026PPT
-
Apr 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Feb 2026PPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
Fabtech provides end-to-end turnkey pharma plant solutions covering design, engineering, procurement, installation, and regulatory validation, while also offering standalone execution services like equipment supply and installation for clients with their own designs.